3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Sarcoma
2
Rectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Jaundice
1
Insulin-Like Growth Factor I, Resistance To
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Carcinoid Tumor
1
Interventions
Gemcitabine
5
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
selpercatinib
2
napabucasin
2
entinostat
2
Irinotecan
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
ganitumab
1
copper dotatate CU-64
1
Therapeutic Irrigation
1
Taxes
1
Sunitinib
1
Paclitaxel
1
Oxaliplatin
1
Ocoxin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Fluorouracil
1
Denosumab
1
Cisplatin
1
Capecitabine
1
Blood Specimen Collection
1
Ascorbic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endocrine Gland Neoplasms
×
ganitumab
×
Gastrointestinal
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts